Search

everythinglearnresearchcommunity

for

Search:↓

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.

Anti-CD19 therapy may help treat SLE and NMOSD.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Baricitinib improved hair loss and arthritis in a lupus patient.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Upadacitinib improved multiple immune-related conditions in one patient.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

The cat improved with treatment but had kidney issues from long-term allopurinol use.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Tislelizumab can cause cutaneous lupus erythematosus.

Promising cancer treatments were found, but the manufacturer closed.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.